The American Journal of Managed Care

Identifying Appropriate Candidates for NGS Testing

Kanwal Raghav, MD, MBBS, discusses appropriate candidates for HER2 testing and current utilization strategies for biomarker testing in mCRC. We’re routinely using next-generation sequencing [NGS] in ...
GEN

Reimbursing NGS Testing

New Working Group to Evaluate Clinical Utility of NGS-Based Testing to Inform Coverage After many years of steady development in DNA sequencing, the scientific community is reaching an exciting ...
The American Journal of Managed Care

Considerations for NGS Testing in mTNBC

Exploring the use of NGS testing in metastatic TNBC and a payer perspective on use of the appropriate companion diagnostic. Transcript Hope S. Rugo, MD: That leads us into the idea of NGS ...
Healthcare Dive

CMS widens NGS test coverage for inherited breast, ovarian cancers

A single NGS test can analyze DNA for millions of genomic variations that can reveal a person's risk for developing certain genetic diseases, which could potentially help guide treatment. NGS-based ...
Labroots

test NGS testing and the single day sequencing workflow

Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic ...
Medscape

First Guideline on NGS Testing in Cancer, From ESMO

Recommendations on the use of next-generation sequencing (NGS) tests for patients with metastatic cancer have been issued by the European Society for Medical Oncology (ESMO), the first recommendations ...
ascopubs.org

Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model

In a hypothetical 1,000,000-member health plan, 2,066 Medicare-insured patients and 156 commercially insured patients were estimated to have mNSCLC and to be eligible for testing. Time-to-test results ...
Healio

Most patients with advanced cancer do not undergo next-generation sequencing testing

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

Meridian Life Science Expands Ambient-Stable NGS Portfolio with the Launch of a Lyophilized Enzymatic DNA Fragmentation Kit

The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of its Lyophilized NGS ...
ascopubs.org

Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non–Small-Cell Lung Cancer

We reviewed electronic medical records of patients with newly diagnosed, untreated metastatic NSCLC from December 2018 to August 2021 and determined the number of days from pathologic diagnosis to NGS ...
Yahoo Finance

Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co ...

Canadian Next-Generation Sequencing (NGS) Market · GlobeNewswire Inc. Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Canada Next-Generation Sequencing (NGS) Market - A Canada and Regional Analysis: ...